Corbus Pharmaceuticals Holdings, Inc.
CRBPNASDAQHealthcareBiotechnology
Regular session
$10.44
+$0.06 · +0.58%
CRBP company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
33
Expensive
Momentum
39
Weakening
Sentiment
74
Bullish
Risk resilience
20
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCorbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Yuval Cohen
- Listed since
- Oct 27, 2014
- Employees
- 36
Market position
Day range
Current $10.44
52-week range
Current $10.44
- Open
- $10.20
- Previous close
- $10.38
- Volume
- 746K
- 1.66× average
- Average volume
- 449.76K
- Average daily volume
- Market cap
- 193.43M USD
- Beta
- 2.62
- Market reference 1
- 50-day average
- $9.1408
- +14.21% above average
- 200-day average
- $9.2702
- +12.62% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 81.54M USD
- P/E (TTM)
- -1.61×
- P/B (TTM)
- 1.98×
- P/S (TTM)
- 0×
- EV / EBITDA
- -1.04×
- Earnings yield
- -72.45%
- Free cash flow yield
- -59.50%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -53.24%
- Return on assets
- -46.69%
- Return on invested capital
- -57.20%
Financial health
- Debt / equity
- 0.04×
- Current ratio
- 8.07×
- Altman Z-score
- -3.79
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 881.71K USD |
| Cost of goods sold | — | 600K USD | — | 1.49M USD | 1.64M USD |
| Gross profit | — | −600K USD | — | −1.49M USD | −757.53K USD |
| Research and development | 70.1M USD | 32.22M USD | 31.17M USD | 16.14M USD | 36.45M USD |
| Selling, general, and administrative | 15.22M USD | 16.5M USD | 13.91M USD | 18.7M USD | 20.43M USD |
| Operating expenses | 85.31M USD | 48.12M USD | 45.08M USD | 33.35M USD | 55.23M USD |
| Interest income | 5.53M USD | 6.31M USD | — | — | — |
| Interest expense | — | 1.87M USD | 2.92M USD | 2.13M USD | 1.83M USD |
| Depreciation and amortization | 233K USD | 600K USD | 641K USD | 1.49M USD | 1.64M USD |
| Operating income | −85.31M USD | −48.72M USD | −45.08M USD | −34.84M USD | −55.99M USD |
| Net income | −78.54M USD | −40.21M USD | −44.6M USD | −55.83M USD | −45.55M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 64%
- 7 beats, 4 misses, 0 met estimates
- Average EPS surprise
- +5.15%
- 11 comparable reports
- Latest EPS result
- -1.81
- Estimate -1.26 · Miss by 43.65%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$33.00
216.09% upsideRating distribution
16 ratingsRecent analyst actions
CRBP news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 14, 2023 | 1:30 | — | — |
Effective Feb 14, 2023
1:30
CRBP peers
ETFs holding CRBP
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.79M0.00%2.3T USD0.03%$377.56-0.18%
iShares Russell 2000 ETFIWM4.14M0.01%81.62B USD0.19%$298.3-0.55%
Vanguard Extended Market ETFVXF1.77M0.00%93.7B USD0.05%$243.65-0.77%
iShares Russell 2000 Value ETFIWN1.62M0.01%14.66B USD0.24%$224.21-0.27%
Fidelity Enhanced Small Cap ETFFESM850.59K0.01%6.03B USD0.28%$47.685-0.53%
Vanguard Russell 2000 ETFVTWO832.19K0.00%17.4B USD0.06%$120.6-0.54%
Dimensional - US Small Cap ETFDFAS606.02K0.00%15.92B USD0.26%$82.605-0.50%
iShares Micro-Cap ETFIWC582.11K0.04%1.53B USD0.60%$197.1-0.52%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 4.79M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $377.56-0.18%
iShares Russell 2000 ETFIWM- Market value
- 4.14M
- Weight
- 0.01%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $298.3-0.55%
Vanguard Extended Market ETFVXF- Market value
- 1.77M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $243.65-0.77%
iShares Russell 2000 Value ETFIWN- Market value
- 1.62M
- Weight
- 0.01%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.21-0.27%
Fidelity Enhanced Small Cap ETFFESM- Market value
- 850.59K
- Weight
- 0.01%
- AUM
- 6.03B USD
- Expense ratio
- 0.28%
- Price / 1D
- $47.685-0.53%
Vanguard Russell 2000 ETFVTWO- Market value
- 832.19K
- Weight
- 0.00%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $120.6-0.54%
Dimensional - US Small Cap ETFDFAS- Market value
- 606.02K
- Weight
- 0.00%
- AUM
- 15.92B USD
- Expense ratio
- 0.26%
- Price / 1D
- $82.605-0.50%
iShares Micro-Cap ETFIWC- Market value
- 582.11K
- Weight
- 0.04%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $197.1-0.52%
Continue in GoAI
Research CRBPresearch.disclaimer